Compare NYAX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | SANA |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | NYAX | SANA |
|---|---|---|
| Price | $59.61 | $4.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $47.50 | $7.83 |
| AVG Volume (30 Days) | 6.9K | ★ 3.5M |
| Earning Date | 03-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $369,938,000.00 | N/A |
| Revenue This Year | $29.95 | N/A |
| Revenue Next Year | $23.27 | N/A |
| P/E Ratio | $89.05 | ★ N/A |
| Revenue Growth | ★ 26.84 | N/A |
| 52 Week Low | $31.90 | $1.26 |
| 52 Week High | $56.99 | $6.55 |
| Indicator | NYAX | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 80.36 | 56.97 |
| Support Level | $50.80 | $4.37 |
| Resistance Level | $55.88 | $4.91 |
| Average True Range (ATR) | 1.14 | 0.28 |
| MACD | 0.74 | 0.04 |
| Stochastic Oscillator | 91.99 | 83.33 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.